IQVIA Holdings Inc. (NYSE: IQV) Stock Competitors & Peer Comparison

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while DHR-PB trades at $1,261.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, IQV's ROE is +0.22%, compared to DHR-PB's ROE of +0.08%. Regarding short-term risk, IQV is more volatile compared to DHR-PB. This indicates higher risk in terms of short-term price fluctuations for IQV.Check DHR-PB's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, TMO has a market cap of 226.6B. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while TMO trades at $609.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas TMO's P/E ratio is 26.33. In terms of profitability, IQV's ROE is +0.22%, compared to TMO's ROE of +0.13%. Regarding short-term risk, IQV is more volatile compared to TMO. This indicates higher risk in terms of short-term price fluctuations for IQV.Check TMO's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, DHR has a market cap of 140.7B. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while DHR trades at $200.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas DHR's P/E ratio is 25.07. In terms of profitability, IQV's ROE is +0.22%, compared to DHR's ROE of +0.08%. Regarding short-term risk, IQV is more volatile compared to DHR. This indicates higher risk in terms of short-term price fluctuations for IQV.Check DHR's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, NTRA has a market cap of 47.1B. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while NTRA trades at $328.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas NTRA's P/E ratio is -249.19. In terms of profitability, IQV's ROE is +0.22%, compared to NTRA's ROE of -0.12%. Regarding short-term risk, IQV is more volatile compared to NTRA. This indicates higher risk in terms of short-term price fluctuations for IQV.Check NTRA's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, A has a market cap of 41.5B. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while A trades at $146.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas A's P/E ratio is 25.29. In terms of profitability, IQV's ROE is +0.22%, compared to A's ROE of +0.20%. Regarding short-term risk, IQV is less volatile compared to A. This indicates lower risk in terms of short-term price fluctuations for IQV.Check A's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, IDXX has a market cap of 39.8B. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while IDXX trades at $504.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas IDXX's P/E ratio is 35.49. In terms of profitability, IQV's ROE is +0.22%, compared to IDXX's ROE of +0.72%. Regarding short-term risk, IQV is more volatile compared to IDXX. This indicates higher risk in terms of short-term price fluctuations for IQV.Check IDXX's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, ILMN has a market cap of 31.2B. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while ILMN trades at $206.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas ILMN's P/E ratio is 41.04. In terms of profitability, IQV's ROE is +0.22%, compared to ILMN's ROE of +0.31%. Regarding short-term risk, IQV is less volatile compared to ILMN. This indicates lower risk in terms of short-term price fluctuations for IQV.Check ILMN's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, WAT has a market cap of 30.5B. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while WAT trades at $408.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas WAT's P/E ratio is 29.85. In terms of profitability, IQV's ROE is +0.22%, compared to WAT's ROE of +0.02%. Regarding short-term risk, IQV is more volatile compared to WAT. This indicates higher risk in terms of short-term price fluctuations for IQV.Check WAT's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, MTD has a market cap of 26.1B. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while MTD trades at $1,293.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas MTD's P/E ratio is 29.73. In terms of profitability, IQV's ROE is +0.22%, compared to MTD's ROE of -12.00%. Regarding short-term risk, IQV is more volatile compared to MTD. This indicates higher risk in terms of short-term price fluctuations for IQV.Check MTD's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, DGX has a market cap of 25.9B. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while DGX trades at $235.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas DGX's P/E ratio is 23.18. In terms of profitability, IQV's ROE is +0.22%, compared to DGX's ROE of +0.14%. Regarding short-term risk, IQV is less volatile compared to DGX. This indicates lower risk in terms of short-term price fluctuations for IQV.Check DGX's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, LH has a market cap of 25.6B. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while LH trades at $311.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas LH's P/E ratio is 18.49. In terms of profitability, IQV's ROE is +0.22%, compared to LH's ROE of +0.12%. Regarding short-term risk, IQV is more volatile compared to LH. This indicates higher risk in terms of short-term price fluctuations for IQV.Check LH's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, GH has a market cap of 21.1B. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while GH trades at $157.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas GH's P/E ratio is -45.09. In terms of profitability, IQV's ROE is +0.22%, compared to GH's ROE of +2.11%. Regarding short-term risk, IQV is less volatile compared to GH. This indicates lower risk in terms of short-term price fluctuations for IQV.Check GH's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while EXAS trades at $104.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas EXAS's P/E ratio is -95.37. In terms of profitability, IQV's ROE is +0.22%, compared to EXAS's ROE of -0.09%. Regarding short-term risk, IQV is more volatile compared to EXAS. This indicates higher risk in terms of short-term price fluctuations for IQV.Check EXAS's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, ILMNV has a market cap of 17B. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while ILMNV trades at $107.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas ILMNV's P/E ratio is N/A. In terms of profitability, IQV's ROE is +0.22%, compared to ILMNV's ROE of N/A. Regarding short-term risk, IQV is more volatile compared to ILMNV. This indicates higher risk in terms of short-term price fluctuations for IQV.Check ILMNV's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, MEDP has a market cap of 16.4B. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while MEDP trades at $587.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas MEDP's P/E ratio is 34.44. In terms of profitability, IQV's ROE is +0.22%, compared to MEDP's ROE of +1.10%. Regarding short-term risk, IQV is more volatile compared to MEDP. This indicates higher risk in terms of short-term price fluctuations for IQV.Check MEDP's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while PKI trades at $115.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas PKI's P/E ratio is 41.45. In terms of profitability, IQV's ROE is +0.22%, compared to PKI's ROE of +0.03%. Regarding short-term risk, IQV is more volatile compared to PKI. This indicates higher risk in terms of short-term price fluctuations for IQV.Check PKI's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, RVTY has a market cap of 13.9B. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while RVTY trades at $124.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas RVTY's P/E ratio is 23.25. In terms of profitability, IQV's ROE is +0.22%, compared to RVTY's ROE of +0.03%. Regarding short-term risk, IQV is less volatile compared to RVTY. This indicates lower risk in terms of short-term price fluctuations for IQV.Check RVTY's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, CRL has a market cap of 13.4B. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while CRL trades at $278.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas CRL's P/E ratio is 28.11. In terms of profitability, IQV's ROE is +0.22%, compared to CRL's ROE of -0.08%. Regarding short-term risk, IQV is more volatile compared to CRL. This indicates higher risk in terms of short-term price fluctuations for IQV.Check CRL's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, ICLR has a market cap of 13B. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while ICLR trades at $169.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas ICLR's P/E ratio is 13.81. In terms of profitability, IQV's ROE is +0.22%, compared to ICLR's ROE of +0.04%. Regarding short-term risk, IQV is less volatile compared to ICLR. This indicates lower risk in terms of short-term price fluctuations for IQV.Check ICLR's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, QGEN has a market cap of 8.8B. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while QGEN trades at $42.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas QGEN's P/E ratio is 17.54. In terms of profitability, IQV's ROE is +0.22%, compared to QGEN's ROE of +0.12%. Regarding short-term risk, IQV is more volatile compared to QGEN. This indicates higher risk in terms of short-term price fluctuations for IQV.Check QGEN's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, RDNT has a market cap of 5.9B. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while RDNT trades at $75.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas RDNT's P/E ratio is 164.11. In terms of profitability, IQV's ROE is +0.22%, compared to RDNT's ROE of -0.02%. Regarding short-term risk, IQV is less volatile compared to RDNT. This indicates lower risk in terms of short-term price fluctuations for IQV.Check RDNT's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, SHC has a market cap of 5.2B. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while SHC trades at $18.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas SHC's P/E ratio is 19.14. In terms of profitability, IQV's ROE is +0.22%, compared to SHC's ROE of +0.27%. Regarding short-term risk, IQV is more volatile compared to SHC. This indicates higher risk in terms of short-term price fluctuations for IQV.Check SHC's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, BLLN has a market cap of 4.5B. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while BLLN trades at $98.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas BLLN's P/E ratio is 141.10. In terms of profitability, IQV's ROE is +0.22%, compared to BLLN's ROE of +0.08%. Regarding short-term risk, IQV is less volatile compared to BLLN. This indicates lower risk in terms of short-term price fluctuations for IQV.Check BLLN's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while SYNH trades at $42.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas SYNH's P/E ratio is 61.40. In terms of profitability, IQV's ROE is +0.22%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, IQV is more volatile compared to SYNH. This indicates higher risk in terms of short-term price fluctuations for IQV.Check SYNH's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, GRAL has a market cap of 3.3B. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while GRAL trades at $76.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas GRAL's P/E ratio is -7.82. In terms of profitability, IQV's ROE is +0.22%, compared to GRAL's ROE of -0.16%. Regarding short-term risk, IQV is less volatile compared to GRAL. This indicates lower risk in terms of short-term price fluctuations for IQV.Check GRAL's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, VCYT has a market cap of 3.3B. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while VCYT trades at $40.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas VCYT's P/E ratio is 20.43. In terms of profitability, IQV's ROE is +0.22%, compared to VCYT's ROE of +0.09%. Regarding short-term risk, IQV is less volatile compared to VCYT. This indicates lower risk in terms of short-term price fluctuations for IQV.Check VCYT's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while OLK trades at $26.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas OLK's P/E ratio is -96.59. In terms of profitability, IQV's ROE is +0.22%, compared to OLK's ROE of -0.07%. Regarding short-term risk, IQV is more volatile compared to OLK. This indicates higher risk in terms of short-term price fluctuations for IQV.Check OLK's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, CDNA has a market cap of 2.6B. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while CDNA trades at $50.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas CDNA's P/E ratio is 59.83. In terms of profitability, IQV's ROE is +0.22%, compared to CDNA's ROE of +0.33%. Regarding short-term risk, IQV is less volatile compared to CDNA. This indicates lower risk in terms of short-term price fluctuations for IQV.Check CDNA's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, WGS has a market cap of 2.5B. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while WGS trades at $85.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas WGS's P/E ratio is 236.85. In terms of profitability, IQV's ROE is +0.22%, compared to WGS's ROE of -0.39%. Regarding short-term risk, IQV is less volatile compared to WGS. This indicates lower risk in terms of short-term price fluctuations for IQV.Check WGS's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, PSNL has a market cap of 1.7B. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while PSNL trades at $16.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas PSNL's P/E ratio is -14.88. In terms of profitability, IQV's ROE is +0.22%, compared to PSNL's ROE of -0.46%. Regarding short-term risk, IQV is less volatile compared to PSNL. This indicates lower risk in terms of short-term price fluctuations for IQV.Check PSNL's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, OPK has a market cap of 1.2B. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while OPK trades at $1.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas OPK's P/E ratio is -5.81. In terms of profitability, IQV's ROE is +0.22%, compared to OPK's ROE of -0.06%. Regarding short-term risk, IQV is less volatile compared to OPK. This indicates lower risk in terms of short-term price fluctuations for IQV.Check OPK's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, CSTL has a market cap of 987.7M. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while CSTL trades at $32.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas CSTL's P/E ratio is -48.98. In terms of profitability, IQV's ROE is +0.22%, compared to CSTL's ROE of -0.04%. Regarding short-term risk, IQV is less volatile compared to CSTL. This indicates lower risk in terms of short-term price fluctuations for IQV.Check CSTL's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, FLGT has a market cap of 580.8M. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while FLGT trades at $20.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas FLGT's P/E ratio is 2045.00. In terms of profitability, IQV's ROE is +0.22%, compared to FLGT's ROE of -0.08%. Regarding short-term risk, IQV is less volatile compared to FLGT. This indicates lower risk in terms of short-term price fluctuations for IQV.Check FLGT's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while GRALV trades at $18.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas GRALV's P/E ratio is N/A. In terms of profitability, IQV's ROE is +0.22%, compared to GRALV's ROE of N/A. Regarding short-term risk, IQV is less volatile compared to GRALV. This indicates lower risk in terms of short-term price fluctuations for IQV.Check GRALV's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, NEO has a market cap of 445M. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while NEO trades at $17.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas NEO's P/E ratio is 133.23. In terms of profitability, IQV's ROE is +0.22%, compared to NEO's ROE of -0.06%. Regarding short-term risk, IQV is less volatile compared to NEO. This indicates lower risk in terms of short-term price fluctuations for IQV.Check NEO's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while CO trades at $2.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas CO's P/E ratio is 5.06. In terms of profitability, IQV's ROE is +0.22%, compared to CO's ROE of +0.11%. Regarding short-term risk, IQV is less volatile compared to CO. This indicates lower risk in terms of short-term price fluctuations for IQV.Check CO's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, PRENW has a market cap of 325.8M. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while PRENW trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas PRENW's P/E ratio is N/A. In terms of profitability, IQV's ROE is +0.22%, compared to PRENW's ROE of -0.49%. Regarding short-term risk, IQV is less volatile compared to PRENW. This indicates lower risk in terms of short-term price fluctuations for IQV.Check PRENW's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, MYGN has a market cap of 323M. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while MYGN trades at $3.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas MYGN's P/E ratio is -26.31. In terms of profitability, IQV's ROE is +0.22%, compared to MYGN's ROE of -0.33%. Regarding short-term risk, IQV is less volatile compared to MYGN. This indicates lower risk in terms of short-term price fluctuations for IQV.Check MYGN's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while FLDM trades at $3.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas FLDM's P/E ratio is -4.74. In terms of profitability, IQV's ROE is +0.22%, compared to FLDM's ROE of +0.18%. Regarding short-term risk, IQV is less volatile compared to FLDM. This indicates lower risk in terms of short-term price fluctuations for IQV.Check FLDM's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, BDSX has a market cap of 219.5M. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while BDSX trades at $26.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas BDSX's P/E ratio is -8.51. In terms of profitability, IQV's ROE is +0.22%, compared to BDSX's ROE of -7.88%. Regarding short-term risk, IQV is less volatile compared to BDSX. This indicates lower risk in terms of short-term price fluctuations for IQV.Check BDSX's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, XGN has a market cap of 169.8M. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while XGN trades at $7.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas XGN's P/E ratio is -8.68. In terms of profitability, IQV's ROE is +0.22%, compared to XGN's ROE of -1.22%. Regarding short-term risk, IQV is less volatile compared to XGN. This indicates lower risk in terms of short-term price fluctuations for IQV.Check XGN's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, IMDX has a market cap of 135.6M. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while IMDX trades at $4.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas IMDX's P/E ratio is -2.82. In terms of profitability, IQV's ROE is +0.22%, compared to IMDX's ROE of +2.72%. Regarding short-term risk, IQV is less volatile compared to IMDX. This indicates lower risk in terms of short-term price fluctuations for IQV.Check IMDX's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while GTH trades at $4.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas GTH's P/E ratio is -1.11. In terms of profitability, IQV's ROE is +0.22%, compared to GTH's ROE of -1.01%. Regarding short-term risk, IQV is more volatile compared to GTH. This indicates higher risk in terms of short-term price fluctuations for IQV.Check GTH's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while GENE trades at $0.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas GENE's P/E ratio is -38.25. In terms of profitability, IQV's ROE is +0.22%, compared to GENE's ROE of -1.85%. Regarding short-term risk, IQV is more volatile compared to GENE. This indicates higher risk in terms of short-term price fluctuations for IQV.Check GENE's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, SERA has a market cap of 76.4M. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while SERA trades at $2.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas SERA's P/E ratio is -3.08. In terms of profitability, IQV's ROE is +0.22%, compared to SERA's ROE of -0.47%. Regarding short-term risk, IQV is less volatile compared to SERA. This indicates lower risk in terms of short-term price fluctuations for IQV.Check SERA's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, PRPO has a market cap of 48.7M. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while PRPO trades at $27.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas PRPO's P/E ratio is -105.08. In terms of profitability, IQV's ROE is +0.22%, compared to PRPO's ROE of -0.08%. Regarding short-term risk, IQV is less volatile compared to PRPO. This indicates lower risk in terms of short-term price fluctuations for IQV.Check PRPO's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, MDXH has a market cap of 36.2M. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while MDXH trades at $0.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas MDXH's P/E ratio is -1.85. In terms of profitability, IQV's ROE is +0.22%, compared to MDXH's ROE of +1.43%. Regarding short-term risk, IQV is less volatile compared to MDXH. This indicates lower risk in terms of short-term price fluctuations for IQV.Check MDXH's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, QUCY has a market cap of 30.7M. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while QUCY trades at $1.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas QUCY's P/E ratio is -0.06. In terms of profitability, IQV's ROE is +0.22%, compared to QUCY's ROE of -3.65%. Regarding short-term risk, IQV is less volatile compared to QUCY. This indicates lower risk in terms of short-term price fluctuations for IQV.Check QUCY's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while AKU trades at $0.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas AKU's P/E ratio is -0.13. In terms of profitability, IQV's ROE is +0.22%, compared to AKU's ROE of -5.32%. Regarding short-term risk, IQV is less volatile compared to AKU. This indicates lower risk in terms of short-term price fluctuations for IQV.Check AKU's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while CEMI trades at $0.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas CEMI's P/E ratio is -0.63. In terms of profitability, IQV's ROE is +0.22%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, IQV is more volatile compared to CEMI. This indicates higher risk in terms of short-term price fluctuations for IQV.Check CEMI's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while ENZ trades at $0.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas ENZ's P/E ratio is -2.24. In terms of profitability, IQV's ROE is +0.22%, compared to ENZ's ROE of -0.39%. Regarding short-term risk, IQV is less volatile compared to ENZ. This indicates lower risk in terms of short-term price fluctuations for IQV.Check ENZ's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while PMD trades at $2.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas PMD's P/E ratio is -5.24. In terms of profitability, IQV's ROE is +0.22%, compared to PMD's ROE of -0.32%. Regarding short-term risk, IQV is more volatile compared to PMD. This indicates higher risk in terms of short-term price fluctuations for IQV.Check PMD's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while ME trades at $0.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas ME's P/E ratio is -0.03. In terms of profitability, IQV's ROE is +0.22%, compared to ME's ROE of -42.03%. Regarding short-term risk, IQV is more volatile compared to ME. This indicates higher risk in terms of short-term price fluctuations for IQV.Check ME's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while MYNZ trades at $3.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas MYNZ's P/E ratio is -0.68. In terms of profitability, IQV's ROE is +0.22%, compared to MYNZ's ROE of -1.80%. Regarding short-term risk, IQV is less volatile compared to MYNZ. This indicates lower risk in terms of short-term price fluctuations for IQV.Check MYNZ's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, BNR has a market cap of 12.8M. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while BNR trades at $12.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas BNR's P/E ratio is -13.89. In terms of profitability, IQV's ROE is +0.22%, compared to BNR's ROE of -0.11%. Regarding short-term risk, IQV is less volatile compared to BNR. This indicates lower risk in terms of short-term price fluctuations for IQV.Check BNR's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, ADVB has a market cap of 11.3M. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while ADVB trades at $8.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas ADVB's P/E ratio is -74.45. In terms of profitability, IQV's ROE is +0.22%, compared to ADVB's ROE of -0.21%. Regarding short-term risk, IQV is less volatile compared to ADVB. This indicates lower risk in terms of short-term price fluctuations for IQV.Check ADVB's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while CHEK trades at $1.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas CHEK's P/E ratio is -0.43. In terms of profitability, IQV's ROE is +0.22%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, IQV is less volatile compared to CHEK. This indicates lower risk in terms of short-term price fluctuations for IQV.Check CHEK's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while CNTG trades at $0.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas CNTG's P/E ratio is -0.23. In terms of profitability, IQV's ROE is +0.22%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, IQV is more volatile compared to CNTG. This indicates higher risk in terms of short-term price fluctuations for IQV.Check CNTG's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, BIAFW has a market cap of 8.5M. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while BIAFW trades at $0.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas BIAFW's P/E ratio is 0.90. In terms of profitability, IQV's ROE is +0.22%, compared to BIAFW's ROE of -2.57%. Regarding short-term risk, IQV is less volatile compared to BIAFW. This indicates lower risk in terms of short-term price fluctuations for IQV.Check BIAFW's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while APDN trades at $5.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas APDN's P/E ratio is -0.10. In terms of profitability, IQV's ROE is +0.22%, compared to APDN's ROE of -7.23%. Regarding short-term risk, IQV is less volatile compared to APDN. This indicates lower risk in terms of short-term price fluctuations for IQV.Check APDN's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, NDRA has a market cap of 7.2M. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while NDRA trades at $5.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas NDRA's P/E ratio is -0.73. In terms of profitability, IQV's ROE is +0.22%, compared to NDRA's ROE of -2.25%. Regarding short-term risk, IQV is less volatile compared to NDRA. This indicates lower risk in terms of short-term price fluctuations for IQV.Check NDRA's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while NVTA trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas NVTA's P/E ratio is -0.00. In terms of profitability, IQV's ROE is +0.22%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, IQV is less volatile compared to NVTA. This indicates lower risk in terms of short-term price fluctuations for IQV.Check NVTA's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while LMDXW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, IQV's ROE is +0.22%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, IQV is less volatile compared to LMDXW. This indicates lower risk in terms of short-term price fluctuations for IQV.Check LMDXW's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while LMDX trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas LMDX's P/E ratio is -0.01. In terms of profitability, IQV's ROE is +0.22%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, IQV is less volatile compared to LMDX. This indicates lower risk in terms of short-term price fluctuations for IQV.Check LMDX's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, BIAF has a market cap of 3.3M. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while BIAF trades at $7.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas BIAF's P/E ratio is -0.93. In terms of profitability, IQV's ROE is +0.22%, compared to BIAF's ROE of -2.57%. Regarding short-term risk, IQV is less volatile compared to BIAF. This indicates lower risk in terms of short-term price fluctuations for IQV.Check BIAF's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while DMTK trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas DMTK's P/E ratio is -0.04. In terms of profitability, IQV's ROE is +0.22%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, IQV is less volatile compared to DMTK. This indicates lower risk in terms of short-term price fluctuations for IQV.Check DMTK's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, NOTV has a market cap of 2.8M. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while NOTV trades at $0.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas NOTV's P/E ratio is -0.03. In terms of profitability, IQV's ROE is +0.22%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, IQV is less volatile compared to NOTV. This indicates lower risk in terms of short-term price fluctuations for IQV.Check NOTV's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while SQL trades at $6.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas SQL's P/E ratio is -0.40. In terms of profitability, IQV's ROE is +0.22%, compared to SQL's ROE of -30.46%. Regarding short-term risk, IQV is less volatile compared to SQL. This indicates lower risk in terms of short-term price fluctuations for IQV.Check SQL's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while AWH trades at $0.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas AWH's P/E ratio is -0.09. In terms of profitability, IQV's ROE is +0.22%, compared to AWH's ROE of +1.62%. Regarding short-term risk, IQV is more volatile compared to AWH. This indicates higher risk in terms of short-term price fluctuations for IQV.Check AWH's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while HTGM trades at $0.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas HTGM's P/E ratio is -0.03. In terms of profitability, IQV's ROE is +0.22%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, IQV is more volatile compared to HTGM. This indicates higher risk in terms of short-term price fluctuations for IQV.Check HTGM's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while BIOC trades at $0.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas BIOC's P/E ratio is -0.01. In terms of profitability, IQV's ROE is +0.22%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, IQV is less volatile compared to BIOC. This indicates lower risk in terms of short-term price fluctuations for IQV.Check BIOC's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, ISPC has a market cap of 204.1K. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while ISPC trades at $1.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas ISPC's P/E ratio is -0.05. In terms of profitability, IQV's ROE is +0.22%, compared to ISPC's ROE of -5.24%. Regarding short-term risk, IQV is less volatile compared to ISPC. This indicates lower risk in terms of short-term price fluctuations for IQV.Check ISPC's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, SQLLW has a market cap of 179.6K. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while SQLLW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas SQLLW's P/E ratio is -0.00. In terms of profitability, IQV's ROE is +0.22%, compared to SQLLW's ROE of -30.46%. Regarding short-term risk, IQV is less volatile compared to SQLLW. This indicates lower risk in terms of short-term price fluctuations for IQV.Check SQLLW's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, WGSWW has a market cap of 5.8K. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while WGSWW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas WGSWW's P/E ratio is -0.00. In terms of profitability, IQV's ROE is +0.22%, compared to WGSWW's ROE of -0.39%. Regarding short-term risk, IQV is more volatile compared to WGSWW. This indicates higher risk in terms of short-term price fluctuations for IQV.Check WGSWW's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while MEUSW trades at $1.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas MEUSW's P/E ratio is N/A. In terms of profitability, IQV's ROE is +0.22%, compared to MEUSW's ROE of -42.03%. Regarding short-term risk, IQV is less volatile compared to MEUSW. This indicates lower risk in terms of short-term price fluctuations for IQV.Check MEUSW's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while NDRAW trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas NDRAW's P/E ratio is N/A. In terms of profitability, IQV's ROE is +0.22%, compared to NDRAW's ROE of -2.25%. Regarding short-term risk, IQV is less volatile compared to NDRAW. This indicates lower risk in terms of short-term price fluctuations for IQV.Check NDRAW's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while DHR-PA trades at $1,841.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, IQV's ROE is +0.22%, compared to DHR-PA's ROE of +0.08%. Regarding short-term risk, IQV is less volatile compared to DHR-PA. This indicates lower risk in terms of short-term price fluctuations for IQV.Check DHR-PA's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, PRXL has a market cap of 0. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while PRXL trades at $88.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas PRXL's P/E ratio is 42.97. In terms of profitability, IQV's ROE is +0.22%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, IQV is more volatile compared to PRXL. This indicates higher risk in terms of short-term price fluctuations for IQV.Check PRXL's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, OCDX has a market cap of 0. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while OCDX trades at $17.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas OCDX's P/E ratio is -42.28. In terms of profitability, IQV's ROE is +0.22%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, IQV is more volatile compared to OCDX. This indicates higher risk in terms of short-term price fluctuations for IQV.Check OCDX's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while BNGOW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas BNGOW's P/E ratio is N/A. In terms of profitability, IQV's ROE is +0.22%, compared to BNGOW's ROE of -0.79%. Regarding short-term risk, IQV is less volatile compared to BNGOW. This indicates lower risk in terms of short-term price fluctuations for IQV.Check BNGOW's competition here

IQVIA Holdings Inc. (NYSE: IQV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IQV stands at 43.1B. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, IQV is priced at $261.77 on the NYSE, while CHEKZ trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IQV currently has a P/E ratio of 21.58, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, IQV's ROE is +0.22%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, IQV is less volatile compared to CHEKZ. This indicates lower risk in terms of short-term price fluctuations for IQV.Check CHEKZ's competition here